Ruxolitinib is a JAK inhibitor of JAK1, JAK2, and JAK3. JAKs, or Janus-associated kinases, are tyrosine kinases found in the cytoplasm that are known to active the signaling of certain growth factor receptors and cytokines. JAK inhibition with ruxolitinib could work as pretreatment for allogeneic stem cell transplantation in myelofibrosis. Ruxolitinib inhibits erythropoiesis from induced pluripotent stem cells (iPSC), but has less inhibitory effect on the self-renewal of CD34+ hematopoietic progenitors.
Peptides & proteins
INCB018424, INCB18424, NCB018424, NCB18424, (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1Hpyrazol-1-yl)-3-cyclopentylpropanenitrile
1) Stübig, T., et al. 2014. Leukemia. PMID: 24569777; 2) Ye, Z., et al. 2014. Stem Cells. 32(1): 269-278. PMID: 24105986
-20°C. Keep away from direct sunlight.
12 months from receipt